Status:
COMPLETED
Evaluation of the Frequency of Occurrence of Joint Pain With Bevacizumab in Patients With Ovarian, Colorectal or Bronchopulmonary Cancer
Lead Sponsor:
University Hospital, Lille
Conditions:
Arthralgia
Eligibility:
All Genders
18+ years
Brief Summary
Self-administered questionnaire survey to determine the presence or absence of joint pain during bevacizumab treatment for lung, ovarian, colorectal cancers. The principal end-point is the frequency ...
Eligibility Criteria
Inclusion
- Patient with ovarian, colorectal or lung cancer receiving bevacizumab therapy
- Male or female (aged ≥18 years old)
- Performance Status (PS) between 0 and 2
- Expected life\> 3 months
- Ability to answer a self-questionnaire
- Obtaining the non-opposition of patient participation
Exclusion
- Pregnant or lactating woman
- Rapid evolution of neoplastic pathology
- Major cognitive disorders that do not allow filling of the self-questionnaire
- Impossibility to submit to medical monitoring for social, psychological or geographical reasons
- Patients under guardianship or curatorship
Key Trial Info
Start Date :
January 3 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2019
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT03455907
Start Date
January 3 2018
End Date
January 31 2019
Last Update
August 20 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Oscar Lambret
Lille, France
2
Hôpital Huriez. CHRU
Lille, France